Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Jae J. Song"'
Autor:
Jeong A. Hong, Soo Jin Choi, Zhezhu Han, Geun-Hyeok Oh, Yeonsoo Joo, Hye Jin Choi, Ji Hyun Lee, Jae J. Song, Suwan Ko, Rong Xu
Publikováno v:
Experimental and Molecular Medicine, Vol 51, Iss 10, Pp 1-20 (2019)
Experimental & Molecular Medicine
Experimental & Molecular Medicine
When the adenoviral protein E1B55K binds death domain-associated protein (Daxx), the proteasome-dependent degradation of Daxx is initiated, and adenoviral replication is effectively maintained. Here, we show that the cellular levels of Daxx differ be
Autor:
Hye Jin Choi, Soo Jin Choi, Dongxu Kang, Geun-Hyeok Oh, Zhezhu Han, Suwan Ko, Suyeon Je, Jihyun Lee, Jae J. Song, Yeonsoo Joo
Publikováno v:
Experimental and Molecular Medicine, Vol 50, Iss 12, Pp 1-19 (2018)
Experimental & Molecular Medicine
Experimental & Molecular Medicine
Transforming growth factor (TGF)-β signaling is increasingly recognized as a key driver in cancer. In progressive cancer tissues, TGF-β promotes tumor formation, and its increased expression often correlates with cancer malignancy. In this study, w
Publikováno v:
Cancer Gene Therapy. 20:82-87
We previously demonstrated that the downregulation of Casitas B-lineage lymphoma (c-Cbl) can sensitize tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in two different ways. One way is to block the rapid degradation
Publikováno v:
Cellular signalling. 27(6)
We previously showed that an increase of cellular Bcl-xL mediates acquired resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and knockdown of Bcl-xL expression greatly sensitized TRAIL-induced cytotoxicity. Here, we show t
Autor:
Hye Jin Choi, Suyeon Je, So Young Kim, Dongxu Kang, Jae J. Song, Yong sic Hwang, Zhezhu Han, Joo Hang Kim, Sujin Kang
Publikováno v:
Cellular signalling. 27(4)
Gemcitabine has been used most commonly as an anticancer drug to treat advanced pancreatic cancer patients. However, intrinsic or acquired resistance of pancreatic cancer to gemcitabine was also developed, which leads to very low five-year survival r
Publikováno v:
Yonsei Medical Journal
Purpose Sorafenib, a multikinase inhibitor, is the standard therapy for patients with advanced-stage hepatocellular carcinoma (HCC). However, resistance develops to the treatment, therefore, we tried to unravel the underlying mechanism in the resista
Publikováno v:
Cancer gene therapy. 20(2)
Tumor cells secrete a variety of cytokines to outgrow and evade host immune surveillance. In this context, transforming growth factor-β1 (TGF-β1) is an extremely interesting cytokine because it has biphasic effects in cancer cells and normal cells.
Autor:
Dongxu Kang, Hye Jin Choi, Eun Kyung Kim, So Y. Kim, Seungha Lee, Jae J. Song, Sujin Kang, Joo Hang Kim
Publikováno v:
Cancer Research. 74:694-694
Gemcitabine as the standard chemotherapy agent to pancreatic cancer has proved effective; however, the response rate remains at 5.4% and the 5-year survival rate is extremely poor. Due to the shortcomings of gemcitabine and the presence of gemcitabin